(Photo Courtesy: www.mersenne.com)
Novozymes announced it has separated its biopharma activities into an independent company called Albumedix.
The new company will be fully owned by Novozymes.
Albumedix will be led by CEO Mr Peter Rosholm, who previously headed Novozymes' Biopharma business.
The leadership team will report to an independent board consisting of three directors from the pharmaceutical industry and two representatives from Novozymes.
The Chairman of the Board, Dr Donald deBethizy, brings more than 15 years of experience in managing and financing life science related technologies, and has played a key role in building and advising several life science companies.